Skyhawk news

Browse:

Skyhawk's proprietary platform revolutionizes disease treatment by developing small molecule therapeutics that modify RNA expression

May 12, 2020

Skyhawk Therapeutics boosts Merck collab pact with added targets, upfront and biobucks

Read

2 min read

June 26, 2018

Celgene inks $60M deal with newcomer Skyhawk to develop RNA drugs for ALS, Huntington’s

Under the deal, Celgene received the exclusive option to license up to five drug candidates born out of Skyhawk’s development platform

Read

1 min read

September 15, 2026

Skyhawk Therapeutics Announces Final Fifteen-Month Results from Phase 1/2 Clinical Trial of SKY-0515 in Huntington’s Disease Patients

The fifteen-month dataset represents the final analysis from the Phase 1/2 study

Read

6 min

July 14, 2026

Skyhawk Therapeutics Announces Expansion of its Global Pivotal FALCON-HD Clinical Trial for SKY-0515 in Huntington’s Disease to the United States, Canada and the United Kingdom

More than ten countries and more than twenty sites are now participating in the Company's global pivotal trial for Huntington's disease, with over 175 patients enrolled

Read

4 min read

March 10, 2026

Skyhawk Therapeutics Appoints Aaron Deves as Chief Commercial Officer to Lead Commercialization of SKY-0515 for Huntington's Disease

Industry veteran brings more than 30 years of experience launching therapies for neurological diseases, including Huntington's disease, and will prepare Skyhawk for the launch of SKY-0515 as early as 2027

Read

2 min read